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Abstract
Background:  Histopathology is a cornerstone in the diagnosis of cervical cancer but the
prognostic value is controversial.
Methods: Women under active follow-up for histologically confirmed primary invasive cervical
cancer were selected from the United States Surveillance, Epidemiology, and End Results (SEER) 9-
registries public use data 1973–2002. Only histologies with at least 100 cases were retained.
Registry area, age, marital status, race, year of diagnosis, tumor histology, grade, stage, tumor size,
number of positive nodes, number of examined nodes, odds of nodal involvement, extent of
surgery, and radiotherapy were evaluated in Cox models by stepwise selection using the Akaike
Information Criteria.
Results: There were 30,989 records evaluable. From 1973 to 2002, number of cases dropped
from 1,100 new cases/year to 900/year, but adenocarcinomas and adenosquamous carcinoma
increased from 100/year to 235/year. Median age was 48 years. Statistically significant variables for
both overall and cause-specific mortality were: age, year of diagnosis, race, stage, histology, grade,
hysterectomy, radiotherapy, tumor size and nodal ratio. The histological types were jointly
significant, P < 0.001. Cause-specific mortality hazard ratios by histological type relatively to non-
microinvasive squamous cell carcinoma were: microinvasive squamous cell carcinoma 0.28 (95%
confidence interval: 0.20–0.39), carcinoma not otherwise specified 0.91 (0.79–1.04), non-mucinous
adenocarcinoma 1.06 (0.98–1.15), adenosquamous carcinoma 1.35 (1.20–1.51), mucinous
adenocarcinoma 1.52 (1.23–1.88), small cell carcinoma 1.94 (1.58–2.39).
Conclusion: Small cell carcinoma and adenocarcinomas were associated with poorer survival. The
incidental observation of increasing numbers of adenocarcinomas despite a general decline suggests
the inefficiency of conventional screening for these tumors. Increased incidence of
adenocarcinomas, their adverse prognosis, and the young age at diagnosis indicate the need to
identify women who are at risk.
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Background
Cancer of the cervix uteri is the second most common can-
cer (after breast cancer) and the third leading cancer mor-
tality (after lung and breast cancer) among women
worldwide [1]. Squamous cell carcinoma (SCC) is the pre-
dominant histological type accounting for three-fourths
of all cervical cancers. Adenocarcinoma and adenosqua-
mous cell carcinoma represent 10–15%, and other or
unspecified histology represent the remaining 10–15%
[2,3]. There is controversy regarding whether or not these
different histological types have any bearing on prognosis
[4-7]. Some authors found that adenocarcinoma had a
poor prognosis [8,9], others found no evidence of patho-
logical type as a risk factor [6,10]. Since histopathology is
a cornerstone in the detection and the diagnosis of cervi-
cal cancer, we believe that clarifying the prognostic value
of pathological type is an important issue that might
influence the management, treatment and surveillance
planning of newly diagnosed cervical cancer. The present
study uses the United States Surveillance, Epidemiology,
and End Results (SEER) population data in order to eval-
uate the prognostic role of histopathological type in inva-
sive carcinoma of the cervix.
Methods
Records of patients under active follow-up were abstracted
from the 9-registries of the SEER [11]. Selected patients
were women with histologically confirmed primary inva-
sive cervical cancer diagnosed between 1973 and 2002.
Tumor histopathologies were classified according to the
SEER's implementation of the International Classification
of Diseases for Oncology (ICDO), Second Edition [11].
Only histopathological types with at least 100 cases were
retained.
Univariate analyses of overall survival (event = death from
any cause) and cause-specific survival (event = death from
cervical cancer) used the Kaplan-Meier method [12].
Multivariate analyses used the proportional hazards mod-
els. The selection of variables combined backward and
forward stepwise selection by minimizing the Akaike
Information Criteria (AIC) [13]. The AIC is computed as
minus twice the log likelihood plus twice the number of
parameters of the model. The AIC penalizes over-parame-
terization, variables are retained only when the model
improves enough to balance the number of parameters.
The variables evaluated were: SEER registry area, age, mar-
ital status, race, tumor histopathology, grade, historical
stage (localized versus regional, metastatic, or unknown),
extent of surgery (hysterectomy versus else), radiotherapy
(prescribed versus none or unknown). Up to four levels of
interactions were considered in the stepwise selection.
More detailed pathological data and AJCC (American
Joint Committee on Cancer) stage was available in a sub-
set of patients. A second analysis was done on that subset
with the detailed variables: AJCC stage, tumor size,
number of removed nodes, number of positive nodes,
and log odds of nodal involvement computed as Log
((number of positive nodes + 0.5)/(number of negative
nodes + 0.5)) [14]. The log odds was used to generalize
the lymph node ratio to node-negative cases. The assump-
tion of proportional hazards were checked using the Sch-
oenfeld residuals method [15] [see Additional File 1]. The
linearity of the functional forms of continuous variables
were verified using the martingale residuals [15] [see
Additional File 2].
For purpose of condensing the report, histopathological
types were grouped as: carcinoma not otherwise specified
(ICDO 8010), squamous cell carcinoma microinvasive
(8076), non-microinvasive squamous cell carcinoma
(8070, 8071, 8072), adenosquamous carcinoma (8560),
adenocarcinoma excluding mucinous (8140, 8260, 8310,
8380), mucinous adenocarcinoma (8480, 8481), and
small cell carcinoma (8041).
Results
1. Trends and characteristics
There were 32,040 cases of histologically confirmed pri-
mary invasive cancer of the cervix and 81 histological
types. Among these, 30,989 records matched the selection
criteria, representing the study population, with 13 histo-
logical types. The median follow-up was 10.5 years. The
predominant histopathological types were invasive squa-
mous cell carcinomas (SCC) accounting for two thirds of
the incidence (n = 20,755). There were notable changes in
the counts of recorded cases over the last three decades.
The overall number of cases diagnosed each year declined
from an average of 1,100 cases per year (peak 1,109–
1,215 per year in 1975–1976) to an average of 900 cases
per year (893–871 in 2000–2002) (Figure 1). In terms of
crude incidence rates, these correspond to a decline from
11.1 to 6.6 cases per 100,000 women per year. Most of the
decline could be attributed to the decline in the incidence
of SCC (Figure 1). The yearly count of carcinoma not oth-
erwise specified (NOS) also declined from an average of
95 per year in 1975 to an average of 30 per year in 2000.
However, the yearly count of adenocarcinomas increased:
non-mucinous from an average of 80 per year (73–89 in
1973–1975) to 175 per year (166–179 in 2000–2002),
adenosquamous from an average of 20 per year (13–29 in
1973–1975) to 45 per year (46–41 in 2000–2002), muci-
nous from almost none (1–3 cases per year in 1973–
1975) to 15 per year (11–17 in 2000–2002) (Figure 1).
Table 1 shows the distribution of patients and tumor char-
acteristics according to the histopathology group. Women
were young in all histological groups. The lowest median
age was 38 years in microinvasive SCC, the highestBMC Cancer 2007, 7:164 http://www.biomedcentral.com/1471-2407/7/164
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median age was 50 years in SCC and in mucinous adeno-
carcinoma, the overall median age was 48 years. By race,
the distribution of histological types were comparable
between White Non-Hispanic and White Hispanic
women. The distribution differed in African-American
women in whom squamous cell types were relatively
more frequent than adenocarcinomas. By tumor charac-
teristics, non-mucinous adenocarcinomas were associated
with smaller tumor size (median 25 mm), less nodal
involvement (log odds -3.6), less advanced stage (71%
stage I, 10% stage II) as compared with SCC (median
tumor size 40 mm, log odds nodal involvement -3.4, 51%
stage I, 19% stage II). Small cell carcinoma was associated
with the most advanced tumor involvement (median
tumor size 45 mm, log odds nodal involvement -2.7, 32%
stage I, 14% stage II). Adenosquamous and mucinous car-
cinomas were associated with intermediary characteris-
tics. Information on surgery was available in 17,994
records. Hysterectomy was generally performed in more
than half of the cases. Information on whether or not radi-
otherapy had been prescribed was available in 30,747
records. Radiotherapy was performed in about 60% of
these cases, except microinvasive SCC and unspecified
carcinoma for which respectively only 4% and 26%
received some form of radiotherapy.
2. Unadjusted survival analyses
The 10-year overall survival was 57.8% (95% confidence
interval 57.2%–58.4%) and the 10-year cause-specific sur-
vival was 74.2% (73.7%–74.8%). There were large statis-
tically significant differences of overall survival between
the histological groups (P < 0.0001) (Figure 2-a). The
longest overall survival was observed with microinvasive
SCC (90.6% at 10-year) and the poorest survival was
observed with small cell carcinoma (31.6% at 10-year)
(Table 2 and Figure 2-a). Between these two groups, the
Numbers of new cervical cancers, by histopathological type Figure 1
Numbers of new cervical cancers, by histopathological type. All graphs are centered around the mean number of 
cases per year (horizontal line). The vertical axes are scaled to highlight the trend within each histopathological type.
C
o
u
n
t
Adeno. excl. muc.
Year
1973 1983 1993 2003
60
100
140
180
220
Adenosquamous
Year
1973 1983 1993 2003
10
30
50
70
Mucinous
Year
1973 1983 1993 2003
0
5
10
15
20
25
Small Cell
Year
1973 1983 1993 2003
0
5
10
15
SCC
1973 1983 1993 2003
500
650
800
950
Carc. NOS
1973 1983 1993 2003
20
50
80
110
Microinvasive
1973 1983 1993 2003
20
70
120
170
C
o
u
n
t
All
1973 1983 1993 2003
800
900
1000
1100
1200
1300BMC Cancer 2007, 7:164 http://www.biomedcentral.com/1471-2407/7/164
Page 4 of 13
(page number not for citation purposes)
ranking from longer to shorter survival was: carcinoma
NOS, non-mucinous adenocarcinoma, invasive SCC, ade-
nosquamous carcinoma, and mucinous adenocarcinoma.
The ranking of the histopathological groups by cause-spe-
cific survival was comparable, from the best cause-specific
survival observed with microinvasive SCC (98.7% at 10-
year), to the poorest survival observed with small cell car-
cinoma (44.5%) (Table 2).
3. Multivariate analysis
In a multivariate analysis for overall mortality, the varia-
bles retained by the stepwise selection were: SEER registry
area, age at diagnosis, year of diagnosis, race, marital sta-
tus, histological type, histological grade, stage, type of sur-
gery, radiotherapy, and interactions between stage,
surgery, and radiotherapy [see Additional File 3]. Figure 2-
b shows the survival according to the histopathological
group that would have been expected after adjustment by
that stepwise selection. For cause-specific mortality, the
SEER registry area and marital status were not significant
while all other variables were significant (Table 3). Histol-
ogy was among the most significant factors, regardless of
whether the analysis was done using grouped histologies
or whether the analysis was done using the distinct histo-
logical subtypes.
Table 1: Invasive tumors: patient and tumor characteristics by histological type
Characteris
tic
Non-
missi
ng 
data
Microinvasiv
e SCC
Carcinoma 
not 
otherwise 
specified
Squamous 
Cell (SCC)
Adenoca. 
excl. 
mucinous
Adeno-
squamous
Mucinous 
adeno-
carcinoma
Small cell 
carcinoma
n = 2910 n = 1688 n = 20755 n = 4015 n = 1120 n = 305 n = 196
Age (1) 30989 38 (31~48) 42 (32~58) 50 (39~64) 47 (37~62) 44 (36~57) 50 (41~66) 48 (35~63)
Marital status 
(married)(2)
27999 1451 (55%) 736 (52%) 9193 (49%) 2102 (58%) 548 (53%) 160 (57%) 95 (51%)
Race 30764
White 
non-hisp (2)
2041 (71%) 1191 (72%) 13797 (67%) 3066 (77%) 785 (70%) 229 (75%) 127 (65%)
White 
hispanic (2)
199 (7%) 96 (6%) 1671 (8%) 236 (6%) 75 (7%) 19 (6%) 14 (7%)
Black (2) 362 (13%) 278 (17%) 3430 (17%) 318 (8%) 157 (14%) 23 (8%) 21 (11%)
Other (2) 279 (10%) 95 (6%) 1735 (8%) 357 (9%) 97 (9%) 34 (11%) 32 (16%)
Tumor size 
(mm) (1)(3)
6352 1 (1~2) 2 (1~53) 40 (17~60) 25 (10~45) 30 (20~50) 29 (20~47) 45 (29~69)
High 
histological 
grade (2)
16378 95 (28%) 248 (86%) 5722 (49%) 821 (28%) 485 (70%) 61 (26%) 142 (100%)
Number of 
nodes 
removed (1)(4)
14178 0 (0-0) 0 (0-0) 0 (0–9) 0 (0–17) 1 (0–18) 5 (0–21) 0 (0–11)
Node-
positive status 
(2)
5243 1 (0%) 9 (18%) 679 (21%) 143 (12%) 92 (24%) 33 (29%) 21 (48%)
Log odds 
nodal 
involvement 
(1)(5)
4497 -3.4 (-3.9~-2.9) -3.1 (-3.7~-1.9) -3.4 (-3.9~-2.5) -3.6 (-3.9~-2.9) -3.3 (-3.8~-2.3) -3.4 (-3.9~-1.9) -2.7 (-3.7~-1.2)
AJCC Stage 
(6)
I (2) 8831 1583 (99%) 373 (70%) 4674 (51%) 1657 (71%) 407 (60%) 100 (54%) 37 (32%)
II (2) 2104 11 (1%) 51 (10%) 1708 (19%) 226 (10%) 74 (11%) 18 (10%) 16 (14%)
III (2) 2223 7 (0%) 50 (9%) 1771 (20%) 216 (9%) 115 (17%) 35 (19%) 29 (25%)
IV (2) 1358 4 (0%) 61 (11%) 925 (10%) 226 (10%) 77 (11%) 31 (17%) 34 (29%)
Hysterectom
y (2)
17994 1553 (72%) 364 (46%) 5302 (48%) 1966 (68%) 540 (67%) 146 (69%) 63 (47%)
Radiotherapy 
(2)
30747 128 (4%) 435 (26%) 13084 (64%) 1819 (46%) 643 (58%) 183 (60%) 120 (62%)
(1) Values are: median (lower ~ upper quartiles).
(2) Values are: number of patients (%). Rounded percentages are computed excluding cases with missing data.
(3) Tumor size: 1 = microscopic focus or foci; 2 = non-microscopic but <= 2 mm.
(4) 9678 cases 0 node examined, 4500 cases with >= 1 node examined.
(5) Log ((number of positive nodes +0.5)/(number of negative nodes + 0.5)). More negative values indicate lower risk of nodal involvement [14].
(6) SEER modified stage grouping: Nx cases (unknown nodal status) are grouped according to the T-stage.BMC Cancer 2007, 7:164 http://www.biomedcentral.com/1471-2407/7/164
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The ranking of the histological groups from best to poor-
est overall survival were: SCC microinvasive (hazard ratio
HR = 0.28), carcinoma NOS (HR = 0.91), SCC non-micro-
invasive (reference, HR = 1), non-mucinous adenocarci-
noma (HR = 1.06), adenosquamous (HR = 1.35),
mucinous (HR = 1.52), and small cell carcinoma (HR =
1.94). The results of the same analysis but using the dis-
tinct histological types instead of groups are shown graph-
ically in Figure 3. The hazard ratios ranged from the
lowest risk histological types (SCC microinvasive,
endometrioid, and papillary adenocarcinoma), through
the intermediary risk types (the three SCC's and the aden-
ocarcinoma NOS), to the highest risk types (clear cell ade-
nocarcinoma, adenosquamous, mucin-secreting, mucous
adenocarcinoma, and small cell carcinoma) (Figure 3).
4. Analyses on reduced subsets
There were 2,458 cases with information on tumor size,
nodal involvement, and with non-missing AJCC staging.
Table 4-A shows the results of the cause-specific analysis
by stepwise selection applied to this subset of patients
with more complete pathological data. The three variables
of tumor size (log transformed to adjust for non-linear-
ity), log odds of nodal involvement, and stage were
retained, but not the number of positive nodes and the
number of nodes removed. The SEER area, marital status,
and radiotherapy were not significant. The histological
groups were jointly significant (P < 0.0001). Their ranking
was comparable to Table 3 aside the non-significant SCC
microinvasive and carcinoma NOS. We noted that the
very large hazard ratio of small cell carcinoma might have
inflated the joint significance of histology, hence the
model was recomputed excluding it. The histological
groups remained jointly significant (P = 0.02).
The analysis was repeated on the same subset in a model
that deliberately ignored tumor size and nodal involve-
ment, and used historical stage instead of AJCC stage
(Table 4-B). SCC microinvasive and carcinoma NOS
remained non significant and the hazard ratios of the
other histological types were almost unchanged. Table 4-
B suggests that historical stage could be an acceptable sur-
Table 2: Kaplan-Meier estimates of overall survival and cause-specific survival by histopathology
Histology ICDO 4-
digits
n 10 year overall survival (95% 
confidence interval)
10 year cause-specific survival 
(95% confidence interval)
All 30989 57.8 (57.2–58.4) 74.2 (73.7–74.8)
Carcinoma not otherwise 
specified (NOS)
8010 1688 71.1 (68.9–73.4) 84.9 (83.1–86.7)
Squamous cell carcinoma 
microinvasive
8076 2910 90.6 (89.4–91.8) 98.7 (98.2–99.1)
Squamous cell carcinoma 
(SCC)
20755 52.3 (51.5–53.0) 69.7 (69.1–70.4)
SCC nonkeratinizing, 
NOS
8072 2692 54.9 (52.9–57.0) 69.1 (67.1–71.0)
SCC large cell, 
keratinizing
8071 2373 54.4 (52.2–56.6) 69.0 (66.9–71.1)
SCC NOS 8070 15690 51.6 (50.7–52.4) 70.0 (69.2–70.8)
Adenosquamous 
carcinoma
8560 1120 50.7 (47.5–53.9) 66.6 (63.5–69.7)
Adenocarcinoma 
excluding mucinous
4015 60.9 (59.2–62.6) 77.9 (76.4–79.3)
Endometrioid 
carcinoma
8380 198 68.9 (59.9–78.0) 87.9 (80.7–95.1)
Adenocarcinoma NOS 8140 3302 61.5 (59.7–63.4) 77.3 (75.7–79.0)
Papillary 
adenocarcinoma, NOS
8260 348 58.9 (53.4–64.4) 81.9 (77.3–86.4)
Clear cell 
adenocarcinoma, NOS
8310 167 47.1 (38.6–55.5) 68.2 (59.9–76.4)
Mucinous 
adenocarcinoma
305 43.0 (36.5–49.5) 62.1 (55.4–68.8)
Mucous 
adenocarcinoma
8480 181 43.6 (34.2–53.1) 64.1 (54.7–73.6)
Mucin-secreting 
adenocarcinoma
8481 124 41.3 (32.1–50.5) 59.1 (49.2–68.9)
Small cell carcinoma 
NOS
8041 196 31.6 (24.5–38.8) 44.5 (36.7–52.4)BMC Cancer 2007, 7:164 http://www.biomedcentral.com/1471-2407/7/164
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rogate to AJCC staging, but with a drawback: non-muci-
nous adenocarcinoma was non-significant in the
incomplete model (P = 0.078, Table 4-B), whereas it was
significant in the complete model (P = 0.016, Table 4-A).
Discussion
The incidence and mortality rates vary between countries
with the highest rates observed in Latin America, South
East Asia and Africa. The rates have declined in the last 40
years in industrialized countries, which reflect the success
of screening [16-19]. Despite this success, the risks might
remain high in the first generation of migrant populations
[20-22]. In the United States, the age-standardized inci-
dence and death rates are higher among African-American
(11.1 new cases and 5.3 deaths per 100,000) and His-
panic-Latino (15.8 new cases and 3.5 deaths per 100,000)
than among White women (8.7 new cases and 2.5 per
100,000) [23]. The incidence of cervical cancer begins to
rise at age 20–29 years and increases rapidly to reach a
peak usually around age 45–49 years in European popu-
lations [1]. The risk of developing an invasive cancer of
the cervix is also higher in the age group 40 to 59 years in
the US population [23]. The proportion of advanced stage
in new invasive cervical cancer was 30% among women
aged <50 years and 52% among women aged >= 50 years
[24]. For these reasons (worldwide population mobility,
risk persistence in migrant populations, higher risk in
minorities, early age occurrence, high proportion of
advanced stages in newly diagnosed cases), cancer of the
Overall survival by histopathology group Figure 2
Overall survival by histopathology group. (a) Unadjusted Kaplan-Meier survival estimates. (b) Expected survival after 
adjustment taking into account registry area, age, year of diagnosis, race, marital status, grade, stage, surgery and radiotherapy, 
for a theoretical patient presenting with average characteristics of the population.
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cervix is a major healthcare issue even in countries where
the incidence has declined.
The present data confirms the overall declining incidence
of cervical cancer, but contrasting with an increasing
number of adenocarcinomas and adenosquamous carci-
nomas (Figure 1). Improved classification might have
contributed to an apparent increase of adenocarcinomas.
Carcinomas that were previously unspecified might have
been better characterized in the more recent years, and
therefore the increase of adenocarcinomas would reflect
only a change in the classifications of the pathological
diagnoses. However, the average drop of unspecified car-
cinomas over three decades was 65/year (= 95–30),
whereas the average increase of adenocarcimas was 135/
year (non-mucinous 175-80 = 95/year, adenosquamous
45-20 = 25/year, mucinous 15-0 = 15/year), that is, the
increase of adenocarcinomas was twice the decline of
unspecified carcinomas. Hence a change of classification
is insufficient to explain the increase [25]. Many authors
have also reported an increasing incidence of adenocarci-
nomas particularly in younger women [1,2,25-31].
In order to gain an understanding of these trends, we need
to consider the current knowledge about the cause(s) of
cervical cancer. There is ample experimental and epidemi-
ological evidence that human papillomavirus (HPV) have
a key role in cervical carcinogenesis [32-38]. The associa-
tion of HPV with adenocarcinomas is similar to that with
squamous cell carcinomas [39-46], though differing by
the role of cofactors, such as tobacco smoking and parity
associated with squamous cell carcinomas but not with
adenocarcinomas, or oral contraceptives and obesity asso-
ciated with adenocarcinomas but less so with squamous
cell carcinomas [47-52]. If indeed HPV infection is deter-
minant for adenocarcinomas, we expected that the
increasing incidence of adenocarcinomas would be pre-
ceded by an increasing prevalence of HPV in the general
population. We found no nationwide monitoring of HPV
prevalence. Nevertheless a most recent survey in 2003–
Table 3: Multivariate analysis of cause-specific mortality based on 30,989 cases of invasive cancer of the cervix
Variable Hazard ratio(3) (95% confi-
dence interval)
P
Demographic characteristics
SEER area
Central registries 0.95 (0.89–1.01) 0.099
Western registries 0.97 (0.91–1.03) 0.308
Age at diagnosis 1.01 (1.00–1.01) <0.001
Year of diagnosis 1.00 (1.00–1.01) 0.013
African-American ethnicity (1) 1.14 (1.07–1.22) <0.001
Marital status (married) (1) 0.99 (0.94–1.04) 0.638
Pathology
Histological type (2) <0.001
SCC microinvasive 0.28 (0.20–0.39) <0.001
Carcinoma not otherwise specified 0.91 (0.79–1.04) 0.168
Adenocarcinoma excl. mucinous 1.06 (0.98–1.15) 0.126
Adenosquamous carcinoma 1.35 (1.20–1.51) <0.001
Mucinous 1.52 (1.23–1.88) <0.001
Small cell 1.94 (1.58–2.39) <0.001
Histological High grade (1) 2.17 (1.93–2.44) <0.001
Localized stage (1) 0.07 (0.05–0.08) <0.001
Treatments and interactions
Hysterectomy (1) 0.26 (0.21–0.31) <0.001
Radiotherapy (1) 1.01 (0.92–1.11) 0.810
Hysterectomy * Radiotherapy 2.05 (1.67–2.52) <0.001
High grade * Radiotherapy 0.60 (0.53–0.69) <0.001
Localized stage * Hysterectomy 2.87 (2.17–3.78) <0.001
Localized stage * Radiotherapy 5.24 (4.36–6.29) <0.001
Localized stage * Hysterectomy * Radiotherapy 0.40 (0.28–0.56) <0.001
(1) Binarized variable, coded 1, versus all other levels of the variable including missing.
(2) Reference level = non-microinvasive squamous cell carcinoma (SCC), all types.
(3) Hazard ratio >1 indicates increased risk of dying from cervical cancer.BMC Cancer 2007, 7:164 http://www.biomedcentral.com/1471-2407/7/164
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2004 reported that 26.8% of women overall tested posi-
tive for one or more strains of HPV [53]. That is a consid-
erable increase as compared to a survey prevalence of
15.1% in 1997–1998 in Arizona among women aged 18–
35 years [54], or compared to estimates of 10% global
prevalence in the early 1990's [55].
We also considered the trends of precursor lesions of ade-
nocarcinomas. The SEER discontinued reporting of cervi-
cal in situ carcinomas in 1996, but cases registered
between 1973 and 1995 were still available. There were
1,161 in situ adenocarcinoma, versus 116,666 other in
situ (51,251 squamous, 47,650 in situ NOS, 17,492 cervi-
cal intraepithelial neoplasia grade 3, and 273 miscellane-
ous). The mean age of the in situ adenocarcinoma patients
was 38.2 years, and the mean age of the other in situ
patients was 33.3 years. We plotted the respective inci-
dences in Figure 4. The plots were scaled using conven-
tional standardization by subtracting the respective
means and dividing by the respective standard deviations.
Figure 4 show that in situ adenocarcinoma increased from
10/year around 1975 to 129/year around 1993. The
increase was proportional to that of other in situ carcino-
mas. This similarity of the trends for the in situ carcino-
mas corroborates the concept of a common etiology. But
the very small number of in situ adenocarcinomas as com-
pared to other in situ carcinomas (Figure 4) or compared
to invasive adenocarcinomas (Figure 1) suggests that the
screening for early glandular lesions had a low sensitivity,
and that adenocarcinomas might have been missed by
conventional screening, possibly due to their location
higher in the cervical canal [31,36,56].
In view of the increasing trend of adenocarcinomas, their
association with HPV, their poorer prognosis, and the
young age at diagnosis discussed farther below, we argue
for the need of improving screening for these tumors and
for the opportunity of HPV vaccination [57-61].
Ranking of histopathological types by cause-specific mortality hazard ratios Figure 3
Ranking of histopathological types by cause-specific mortality hazard ratios. The hazard ratios were computed tak-
ing into account registry area, age, year of diagnosis, race, marital status, grade, stage, surgery, and radiotherapy. Horizontal 
bars: 95% confidence interval. Size of the boxes drawn as a function of the number of patients.
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Some of the most extensive studies from the literature
found that histopathological types were of limited prog-
nostic value, or were significant only in some selected
comparisons, or only within some subsets [6,10,62]. In a
large study of 11,157 patients from the Patient Care and
Evaluation Study comparing adenocarcinoma, squamous
cell carcinoma, and adenosquamous carcinoma, Shingle-
ton et al. found no significant differences in 5-year sur-
vival among the three tissue types [6]. In an earlier study
of the SEER data, no evidence was found of survival differ-
ences between squamous cell carcinoma and adenocarci-
noma [62]. In an investigation of 17 histological subtypes
of non-squamous cell carcinoma of the uterine cervix
identified from the Cancer Registry of Norway and histo-
logically verified, Alfsen et al found that histological sub-
typing lacked significance except small cell carcinoma
which was the only histologic subgroup of independent
importance for prognosis [10].
These negative results could be interpreted as demonstrat-
ing that histopathology genuinely lack in sensitivity for
predicting tumor behavior, or caused by wide variation in
histopathologic definitions and criteria, lack of standard-
ization in criteria and lack of reproducibility in their
application [5]. The lack of reproducibility not only
between different observers but also by the same observer
was spotlighted in a review of tumor slides from non-
squamous cell carcinomas of the uterine cervix [63].
Slides previously reviewed [10] were blindly re-diagnosed
more than one year later by the same pathologist (evalua-
tion of intraobserver agreement) and independently by
another pathologist (evaluation of interobserver agree-
ment). The overall intraobserver and interobserver kappa
index of agreement were respectively 0.53 and 0.44, and
the agreement was less than moderate (kappa < 0.40) in
respectively 6 and 7 out of 17 histologic types [63]. The
agreement was fair to poor for mixed carcinomas and ade-
nocarcinomas NOS, poor for villoglandular and adenosq-
uamous carcinomas, and the distinction of
adenocarcinoma in situ from well-differentiated carci-
noma proved difficult. Agreement for small cell and
undifferentiated carcinomas was moderate (kappa > 0.50)
Table 4: Multivariate analysis of cause-specific mortality based on 2,458 cases with complete pathological data
AB
Model including tumor 
size and nodal variables
Model ignoring tumor 
size and nodal variables
Variable Hazard ratio(6) (95% confi-
dence interval)
PH a z a r d  r a t i o (6) (95% confi-
dence interval)
P
Pathology
Histology (1) <0.001 <0.001
SCC microinvasive 1.26 (0.40–4.04) 0.693 0.61 (0.19–1.93) 0.407
Carcinoma NOS 0.93 (0.40–2.17) 0.871 1.35 (0.60–3.06) 0.472
Adenocarcinoma excl. mucinous 1.43 (1.07–1.90) 0.016 1.29 (0.97–1.72) 0.078
Adenosquamous carcinoma 1.60 (1.14–2.24) 0.007 1.58 (1.13–2.22) 0.008
Mucinous 1.94 (1.07–3.49) 0.028 2.08 (1.16–3.75) 0.015
Small cell 7.03 (3.95–12.5) <0.001 7.59 (4.28–13.4) <0.001
Histological grade 3–4 (2) 1.56 (1.26–1.93) <0.001 1.83 (1.48–2.26) <0.001
Log tumor size (mm) (3) 1.89 (1.55–2.31) <0.001
Log odds of nodal involvement (4) 1.26 (1.15–1.38) <0.001
Stage
Historical stage localized (2) 0.24 (0.19–0.31) <0.001
Stage II (5) 0.99 (0.62–1.58) 0.966
Stage III (5) 2.31 (1.70–3.14) <0.001
Stage IV (5) 2.57 (1.64–4.04) <0.001
Other
Year of diagnosis 0.97 (0.94–0.99) 0.016 0.96 (0.94–0.99) 0.011
African-American ethnicity (2) 1.47 (1.09–1.97) 0.011 1.55 (1.16–2.09) 0.004
Hysterectomy (2) 0.61 (0.47–0.80) <0.001 0.41 (0.32–0.52) <0.001
(1) Reference level = non-microinvasive squamous cell carcinoma (SCC), all types.
(2) Binarized variable, coded 1 versus all other levels of the variable including missing.
(3) Untransformed tumor size displayed marked non-linearity.
(4) Log ((number of positive nodes + 0.5)/(number of negative nodes + 0.5)) [14].
(5) AJCC 3rd edition. Reference level = stage I.
(6) Hazard ratio >1 indicates increased risk of dying from cervical cancer.BMC Cancer 2007, 7:164 http://www.biomedcentral.com/1471-2407/7/164
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but the pathologists agreed upon the diagnosis only in 2/
3 of these diagnoses.
On consideration that the SEER data come from widely
differing practices and cover a large time period, there is a
priori no reason to believe that the lack of agreement
would be any better in the SEER data. Notwithstanding,
our analyses find that histology is an important independ-
ent prognostic factor. Moreover, the synoptic view of Fig-
ure 3 corresponds surprisingly well with what might be
expected of prognosis by the ordering of the hazard ratios:
the lowest risk microinvasive SCC [64], the good progno-
sis of endometrioid carcinoma [65], the low risk but
uncertain behavior of papillary adenocarcinoma [66], the
closely clustered SCC types, the slightly poorer survival of
clear cell adenocarcinoma [67], the adenosquamous usu-
ally recognized as an aggressive neoplasm [4,68,69], the
poor prognosis of mucinous adenocarcinomas [70], and
the consistently poorest survival of small cell carcinoma
[10]. The histopathological types appear to represent a
continuum with largely overlapping confidence intervals
which nevertheless do not preclude recognizing distinct
clusters (Figure 3). Furthermore the different time trends
summarized in Figure 1 suggest that the different his-
topathologies correspond to distinct biological entities.
Alfsen et al argued that the lack of significance for his-
topathologic subtyping of adenocarcinomas indicates the
need for a simplified nomenclature for these tumors of
the uterine cervix [10]. Most likely uncertainty or lack of
reproducibility of histopathological subtyping also hap-
pened in the SEER data in view of the large confidence
intervals (Table 3, 4). This did not preclude the extraction
of useful data. Our results argue that histopathologic types
identify different tumors, provide valuable prognostic
information, and are valuable for the early detection of
unexpected trends.
We acknowledge several limitations to this study. Details
such as whether the tumors were diagnosed by screening
or by symptom occurrence, the type of screening, the HPV
status, the status of surgical margins in operated cases, the
radiation treatment procedures, the combination or not
with chemotherapy, the presence or not of patient's co-
morbidities, were not available. The study could not
assess to which extent histopathology should affect treat-
ment decision. Factors other than histological type, such
as tumor grade, stage or patient's ethnicity, were also
important. These factors are not discussed, but clearly they
show that the management of the patients cannot be
based on histopathology alone. There were many missing
data. Only 8% of the cases (2,458 out of 30,989) had full
pathological measurements. Even though the concord-
ance of the analyses based on the reduced subsets suggest
that the results are robust, the possibility of unknown
confounding cannot be excluded. For all these reasons,
caution is required, the results should only be considered
as explorative.
Conclusion
In the present study, histological type was found to be an
important independent prognostic factor in cervical can-
cer. The histological types associated with the poorest sur-
vival were small cell carcinoma, several subtypes of
adenocarcinoma-mucinous, clear cell, and common type
of adenocarcinoma- and adenosquamous carcinoma.
Incidentally the data confirmed an increasing trend of
adenocarcinomas despite an overall decline in the inci-
dence of cervical cancers. The majority of the tumors were
diagnosed in women younger than 50 years. The combi-
nation of young age, increasing trend, and poorer progno-
sis of adenocarcinomas questions the efficiency of
conventional screening for these tumors, indicate the
need to identify women who are at risk and who might
most benefit from vaccination.
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